ITEM 3.
|
SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
|
The Flagship Funds purchased the shares set forth in Item 5 using funds from working capital. The Flagship Funds used an aggregate of approximately $32,065,470
(including brokerage commissions) of such working capital to purchase the Common Stock reported in this Schedule 13D.
ITEM 4.
|
PURPOSE OF TRANSACTION
|
On June 18, 2019, each of Flagship Fund VI and Nutritional LTP acquired 4,444,444 shares pursuant to an underwritten public offering of common stock by
the Issuer (the Offering). The purchase price was $2.25 per share.
The Reporting Persons acquired the shares of Common Stock set forth in
Item 5 and hold their shares of Common Stock for investment purposes. Subject to a number of factors, including market conditions and their general investment and trading policies, the Reporting Persons may, in the ordinary course of their business,
dispose of the shares of Common Stock that they beneficially own. These dispositions may occur in open market transactions, privately negotiated transactions or through other methods. Additionally, the Flagship Funds may distribute the shares of
Common Stock that they directly hold to their respective limited partners.
Dr. Afeyan is a
co-founder
and
director of the Issuer. The Reporting Persons, either directly or indirectly through Dr. Afeyan, may engage in discussions from time to time with the Issuers board of directors, the Issuers management or the Issuers other
stockholders. These discussions may be with respect to (i) acquiring or disposing shares of Common Stock or other securities of the Issuer (collectively, the
Securities
); (ii) maintaining or changing the Issuers
business, operations, governance, management, strategy or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D.
Additionally, the Reporting Persons may acquire additional Securities through open market transactions, privately negotiated transactions or other methods.
The information set forth in Item 6 below is incorporated by reference in its entirety into this Item 4.
ITEM 5.
|
INTEREST IN SECURITIES OF THE ISSUER
|
(a)-(b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13
is based on 69,913,410 outstanding shares of Common Stock as of June 18, 2019 consisting of the sum of (i) 41,094,832 shares of Common Stock outstanding as of March 31, 2019, (ii) 26,666,667 shares of Common Stock issued in the Offering
and (iii) 2,151,911 shares of Common Stock issued as a result of the exercise by the underwriters of their over-allotment option, as set forth in the Issuers prospectus supplement relating to the Offering filed with the Securities and Exchange
Commission on June 14, 2019 (the Prospectus Supplement).
VentureLabs IV, Flagship Fund IV and Flagship Fund
IV-Rx
directly hold 2,734,994 shares, 8,022,420 shares, and 1,925,462 shares of Common Stock, respectively. Flagship Fund IV, as the manager of VentureLabs IV, may be deemed to beneficially own the shares directly
held by VentureLabs IV. Flagship Fund IV GP, as the general partner of the Flagship Fund IV Funds, may be deemed to beneficially own the shares directly held by the Flagship Fund IV Funds.
Nutritional LTP directly holds 4,444,444 shares of Common Stock. Nutritional LTP GP, as the general partner of Nutritional LTP, may be deemed to beneficially
own the shares directly held by Nutritional LTP.
Flagship Fund VI directly holds 4,444,444 shares of Common Stock. Flagship Fund VI GP, as the general
partner of Flagship Fund VI, may be deemed to beneficially own the shares directly held by Flagship Fund VI. Flagship Pioneering, as the general partner of Flagship Fund VI GP, may be deemed to beneficially own the shares directly held by Flagship
Fund VI.
Dr. Afeyan and Mr. Kania, as the managers of Flagship Fund IV GP, may be deemed to beneficially own the shares directly held by the
Flagship Fund IV Funds. While Mr. Kania is retired from Flagship Pioneering, he continues to serve as a manager of Flagship Fund IV GP. Dr. Afeyan, as the sole member and manager of Nutritional LTP GP and as CEO and sole shareholder of
Flagship Pioneering, may be deemed to beneficially own the shares directly held by each of Nutritional LTP and Flagship Fund VI. In addition, Dr. Afeyan holds options to purchase an aggregate of 60,000 shares of Common Stock of the Issuer that
are exercisable within 60 days of the date hereof received my him for his service as a director of the Issuer. Dr. Afeyan also holds 15,141 shares of Common Stock directly.
14